Overview

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis

Status:
Not yet recruiting
Trial end date:
2023-08-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of guselkumab on coronary flow reserve (CFR), measured by transthoracic doppler-echocardiography, in participants with moderate-to-severe psoriasis and intermediate cardiovascular risk.
Phase:
Phase 4
Details
Lead Sponsor:
Janssen-Cilag Ltd.